NEWCELX
Live / Applied — New application — not yet assigned to an examiner (as of 19 Feb 2026)
What this means for you
Not registered yet, but its 08 Dec 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79444171
- Mark type
- Stylized text
- Filed
- 08 Dec 2025
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of degenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of metabolic disorders; pharmaceutical preparations, namely cell therapy for the treatment of diabetes and ALS; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of ALS; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of narcolepsy; stem cells for medical purposes; pharmaceutical compositions containing stem cells; pharmaceutical compositions containing stem cells for the treatment of degenerative diseases; pharmaceutical compositions containing stem cells for the treatment of neurodegenerative and metabolic diseases.
- Class 042 — Scientific and technological services: Research and development services in the field of biotechnology; research and development services in the field of pharmaceutical preparations; research and development services in the field of stem cells; research and development services in the field of cell therapy; research and development of induced pluripotent stem cells; research and development services in the field of pharmaceutical preparations, namely research and development of proprietary cell lines for the treatment of diabetes and ALS; research and development services in the field of pharmaceutical preparations, namely research and development of pluripotent stem cells for the treatment of neurodegenerative and metabolic diseases; scientific research in the medical and pharmaceutical field, and consultancy and information relating thereto; design and development of technology for cell therapy for the treatment of degenerative diseases; pharmaceutical drug development services; development of products for others in the field of pharmaceuticals; scientific services relating to processing human cells; medical and scientific research and development of human stem cells; scientific and technological services in the field of regenerative medicine; scientific and technological services and research and development relating thereto in the field of stem cell-based regenerative therapies for the treatment of neurodegeneration and metabolic disorders; medical and scientific research and development in the field of regenerative medicine; pharmaceutical research and development services in the field of cell regeneration and engineering.
Owner
- KADIMASTEM LTD., IL
Prosecution history
- 23 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 23 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 19 Feb 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB